Exelixis vs Halozyme Therapeutics: revenue, profit, margins and growth compared
Exelixis brought in $2.3B of revenue in fiscal 2025, Halozyme Therapeutics $1.4B in fiscal 2025. Revenue changed by +7.0% at Exelixis and +37.6% at Halozyme Therapeutics on the year before, so Halozyme Therapeutics grew faster. Exelixis kept 33.7% of its revenue as net profit, Halozyme Therapeutics 22.7%. Free cash flow was $875.8M at Exelixis and $644.6M at Halozyme Therapeutics.
Fiscal years as each company reports them; the two may end in different months.
Questions about Exelixis and Halozyme Therapeutics
Which is bigger by revenue, Exelixis or Halozyme Therapeutics?
Exelixis is bigger by revenue: $2.3B in fiscal 2025, against $1.4B for Halozyme Therapeutics in fiscal 2025.
Which keeps more of its revenue as profit, Exelixis or Halozyme Therapeutics?
Exelixis had a net margin of 33.7% in fiscal 2025; Halozyme Therapeutics had 22.7% in fiscal 2025.
Which grew revenue faster, Exelixis or Halozyme Therapeutics?
In their latest fiscal years revenue changed by +7.0% at Exelixis and +37.6% at Halozyme Therapeutics.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.